

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) pour

Other specified malignant neoplasms of breast

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) pour

Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section

Targeted therapies

Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) pour

Other specified melanoma of skin

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) pour

Other specified melanoma of skin

Crizotinib

Section	Indications
Targeted therapies Oral > Solid: 200 mg; 250 mg Oral > Solid > capsule: 200 mg; 250 mg	Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive

Dabrafenib

Section	Indications
Targeted therapies Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dasatinib

Section	Indications
Targeted therapies Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myeloid leukaemia, not elsewhere classified

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Erlotinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Everolimus

Section	Indications
Targeted therapies Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)	Other specified gliomas of brain

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib pour

Other specified malignant neoplasms of bronchus or lung

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Nilotinib

Section

Targeted therapies

Oral > Solid: 150 mg capsule; 200 mg capsule

Indications

Chronic myeloid leukaemia, not elsewhere classified

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Pertuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Rituximab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia

Trametinib

Section	Indications
Targeted therapies Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Trastuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib pour

Other specified melanoma of skin

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma